Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M

DYADIC INTERNATIONAL INC

2025-Q3 EPS reported -$0.15 vs consensus -$0.04 ▼ miss (-239.4%)

Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.
Net loss of $203K vs $1.614M a year ago; operating loss fell to $203K from $1.720M.
Cash & investment-grade securities at $10.0M as of Sep 30, 2024, up from $7.3M at Dec 31, 2023.
Received $1M milestone from Proliant for animal-free recombinant albumin; first product launch expected H1 2025.
Advanced C1-produced Mpox antigen with ViroVax (4.5 g/L in 7 days); preclinical studies start Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.